There are compounds available that can target some of the molecular abnormalities identified (HER2 amplification in mucinous carcinoma, neovascularization and VEGF signaling in clear cell carcinoma, hormone receptor signaling in low-grade serous carcinoma, and KIT mutations in dysgerminoma); future studies should focus on both identifications of additional targets; rational preclinical studies and subtype-specific clinical trials of targeted therapies aimed at promising molecular targets. The gene discussed is NR4A1; the disease is mucinous adenocarcinoma.